Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness

E HELEN RAMSDALE, MARILYN M MORRIS, ROBIN S ROBERTS, FREDERICK E HARGREAVE

From the Firestone Regional Chest and Allergy Unit, Department of Medicine, St Joseph's Hospital, and Departments of Medicine and of Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

ABSTRACT The response to inhaled methacholine is increased in patients with chronic airflow obstruction, but it is not known whether this is due to true hyperresponsiveness or is a result of the airflow obstruction. In asthmatics the response to methacholine correlates with the bronchoconstriction produced by hyperventilation of cold dry air. We studied 27 patients with a history of smoking and chronic bronchitis with a range of severity of airflow obstruction. Bronchial responses to methacholine (expressed as the provocation concentration causing a fall in FEV₁ of 20%—PC₂₀) and isocapnic hyperventilation of cold dry air were measured. In 19 patients the PC₂₀ was less than 8 mg/ml (that is, in the asthmatic range) but only three developed bronchoconstriction in response to hyperventilation. There was a linear correlation between the log PC₂₀ and the FEV₁ (r = 0.86, p < 0.001). The results suggest that in patients with chronic airflow obstruction the response to methacholine is determined by the degree of airflow obstruction, and cannot be used in the diagnosis of asthma in the absence of additional information.

The response to inhaled methacholine is increased in patients with chronic airflow obstruction.¹⁻⁵ It is not known, however, whether this represents a true increase in bronchial responsiveness or whether it reflects an apparent increase secondary to the airflow obstruction.⁶⁻⁷ Appropriate interpretation of responses to methacholine inhalation tests in the presence of airflow obstruction is necessary if the test is to be used in epidemiological studies or for the diagnosis and assessment of the severity of asthma. In addition, we may improve our understanding of underlying mechanisms in airflow obstruction.

In asthmatic patients methacholine bronchial responsiveness correlates with responsiveness to isocapnic hyperventilation of cold air.⁸⁻⁹ The increased responsiveness of the airway can therefore be demonstrated by tests which depend on two different mechanisms. The demonstration of a correlation between responsiveness to methacholine and cold air in patients with chronic airflow obstruction would support the presence of bronchial hyperresponsiveness. Alternatively, a correlation between the response to methacholine and the degree of airflow obstruction, together with a lack of correlation with the response to hyperventilation of cold air, would confirm the importance of obstruction, and suggest that there may not be true bronchial hyperresponsiveness. We therefore compared the response to methacholine with the response to isocapnic hyperventilation of cold air in patients with chronic bronchitis having a range of severity of airflow obstruction.

METHODS

SUBJECTS Twenty seven patients attending the Firestone Regional Chest and Allergy Clinic were selected by their availability and willingness to enter the study (table 1). All had a history of cigarette smoking, with the development of cough and sputum in adult life. Fourteen were current smokers, with cough and sputum on most days for at least three months for two consecutive years.¹⁰ Nine were ex-smokers who

Address for reprint requests: Dr FE Hargreave, Firestone Regional Chest and Allergy Unit, 50 Charlton Avenue East, Hamilton, Ontario, Canada L8N 1Y4.

Accepted 25 June 1984
continued to produce sputum, and three ex-smokers had airflow obstruction with previous but not current cough and sputum. The sputum was not purulent during the study, and the baseline FEV₁ varied by less than 10% on the three study days. All patients had an FEV₁ greater than 0.8 litres. Subjects with a lower FEV₁ were excluded owing to the difficulty of interpreting 20% changes in FEV₁ when this is less than 150 ml. None of the patients gave a history which suggested to the attending physician that they had asthma and the FEV₁, if reduced, did not increase to predicted values after salbutamol. The patients had stable chronic airflow obstruction at the time of the study. The response to prednisone was documented at the end of the study in the patients with an FEV₁ less than 60% of the predicted value as part of their normal clinic assessment, provided that there were no medical contraindications; patient 11, with an FEV₁ of 66% predicted, received prednisone at the request of her physician. All patients gave written consent, and the study was approved by the hospital research committee.

STUDY DESIGN
The patients attended the laboratory on three study days, at the same time of day, and rested for 15 minutes. They had withheld inhaled bronchodilator for eight hours, short acting theophylline for 24 hours, and long acting theophylline for 48 hours. On day 1 the patients' characteristics were documented, skin prick tests for common allergens were performed, and FEV₁ and vital capacity (VC) were measured before and after administration of salbutamol (200 μg). On day 2 a methacholine inhalation test was performed and on day 3 isocapnic hyperventilation of cold air. On each of the three days blood was taken for a total eosinophil count, and any morning sputum was examined for eosinophils. The study was completed within three weeks. After the main study those patients with an FEV₁ less than 60% of the predicted value received a 10 day course of prednisone (40 mg daily) if there was no medical contraindication.

QUESTIONNAIRE AND TESTS
The questionnaire from the epidemiology standardisation project of the American Thoracic Society was used. Supplementary questions related specifically to the presence or absence of symptoms consistent with asthma were added, such as nocturnal symptoms that disturbed sleep and exacerbations caused by cold air, inhaled irritants, or exercise.

Skin tests were performed by the modified prick technique with extracts of 16 common allergens. Responses were measured after 10 minutes and were regarded as positive if the weal was equal to or greater than 2 mm.
All FEV₁ and VC measurements were made on a Collins 9 litre water spirometer. Three FEV₁ and VC manoeuvres were recorded, and if the FEV₁/VC% was greater than 75% and the FEV₁ greater than 80% of the predicted values then the maximum mid expiratory flow rate (MMEF) was measured by means of a forced vital capacity manoeuvre. Salbutamol (200 µg, two puffs) was administered by the experimenter from a metered dose inhaler. The inhaler was held 3 cm from the subject's mouth, while inspiratory flows continued after each inhalation. MMEF was measured 20 minutes after inhalation of cold air. Inhalations were discontinued once the FEV₁ had fallen by 20% or the subject had reached his maximum voluntary ventilation. The respiratory heat loss (RHL) in kilocalories/minute (kcal/min) was calculated for each level of ventilation by the formula 

\[ \text{RHL} = V_E (HC [Ti - Te] + HV [WCi - WCe]) \]

where \( V_E \) = minute ventilation (l/min), \( HC \) = heat capacity of air (0-000304 kcal/min), \( Ti \) = inspired air temperature (°C), \( Te \) = expired air temperature (°C), \( HV \) = latent heat of vaporisation of water (0-00058 kcal/mg), \( WCi \) = water content of inspired air (mg/l) and \( WCe \) = water content of expired air (mg/l). The inspired air was dry. Expired air was assumed to be fully saturated at the expired temperature and the water content was obtained from standard saturation temperature relationships. If bronchoconstriction occurred the response was expressed as the provocation dose of RHL to cause a fall in FEV₁ of 10% (PD₁₀) and was obtained from the log dose response curve by linear interpolation of the last two points (see under “Analysis” for the method of determining whether sufficient RHL had been achieved).

Blood smears were stained with Wright's stain, 400 white cells were counted, and the number of eosinophils was expressed as mm⁻³. Sputum smears were similarly stained, and the percentage of eosinophils in relation to the total number of white cells was recorded. The upper limit of normal for blood eosinophils was 400 mm⁻³ and 10% for sputum.

**Analysis**

Natural logarithms of PC₂₀ were used for all calculations. Linear regression analysis was performed by the method of least squares to investigate the relationship between PC₂₀ and baseline spirometric values. Patients who had no features to suggest the presence of additional asthma were treated as a separate group for further analysis. Coincidence of the regression lines was tested by examining the differences in slopes and intercepts, an unpaired \( t \) test being used.

The maximum RHL which can be generated by a patient is determined by the maximum voluntary ventilation, which in turn depends on the FEV₁. There was therefore a possibility that our patients with a reduced FEV₁ could not achieve the amount of RHL which would produce a bronchoconstrictor response in asthmatics with a similar PC₂₀. The relationship between bronchial responsiveness to
methacholine and cold air in asthmatics may be expressed by the equation 
\[ \log_{10} \text{PD}_{10} = 0.048 + 0.3291 \log \text{PC}_{20} \]
We derived a predicted \( \text{PD}_{10} \) (kcal/min) for our patients from this equation, to determine whether they had achieved sufficient RHL.

**Results**

In 19 patients bronchial responsiveness to methacholine was less than 8 mg/ml—that is, in the asthmatic range (table 2). Eighteen of these had evidence of airflow obstruction (in 16 the FEV, was less than 80% predicted, in two the FEV,VC% was less than 78%), and in the remaining one there was a reduced MMEF, with only a mild increase in bronchial responsiveness.

There was a linear correlation between the log \( \text{PC}_{20} \) and the degree of airflow obstruction, whether this was expressed as FEV, (l) \( r = 0.86, p < 0.001 \), (fig), FEV, (% predicted) \( r = 0.79, p < 0.001 \), or FEV,VC% \( r = 0.81, p < 0.001 \). The more severe the airflow obstruction the greater was the increase in bronchial responsiveness to methacholine (that is, the lower was the PC_{20}).

The relationship between bronchial responsiveness to methacholine and cold air in asthmatic patients is such that we expected most of the patients with a PC_{20} of less than 8 mg/ml to develop bronchoconstriction in response to hyperventilation of cold air. Only three subjects, however, (Nos 10, 12 and 16), developed bronchoconstriction and had a measurable PD_{10}, which was associated with symptomatic chest tightness (table 2). In the remaining 16 patients with a PC_{20} in the asthmatic range there was a discrepancy between the bronchial responsiveness to methacholine and cold air. Thirteen of these patients achieved sufficient RHL to produce a bronchoconstrictor response in asthmatics with a similar PC_{20} (table 2). The three patients with a PC_{20} greater than 5 mg/ml did not achieve sufficient RHL, but this is not an unusual finding in cases of mild asthma.

The three patients who developed bronchoconstriction in response to cold air all had a greater response to methacholine than the others with a similar amount of airflow obstruction (fig). This suggests that in these patients the response to
Relationship bronchial obstruction (FEV₁) and bronchial responsiveness to methacholine (log PC₂₀ mg/ml).

- Patients responsive to cold air. The solid line represents the regression line ($r = 0.86$, $p < 0.001$).

methacholine was determined partly by the airflow obstruction and partly by true bronchial hyperresponsiveness.

It seemed possible that 17 patients had asthma as well as chronic bronchitis since they had atopy, eosinophilia, a bronchoconstrictor response to RHL, or an increase in FEV₁ of more than 15% after treatment with salbutamol or steroid (tables 1 and 2). Data on the remaining 10 patients (Nos 2, 7, 8, 13, 15, 18–20, 22, 23) were therefore analysed as a separate group. There was a strong linear relationship between log PC₂₀ and FEV₁ (l), ($r = 0.90$, $p < 0.001$). There was no significant difference between this regression line (slope or intercept) and that of the group as a whole ($p > 0.5$).

Discussion

This study has confirmed that the bronchial response to inhaled methacholine is increased in patients with chronic bronchitis when airflow obstruction is present. In addition, the degree of hyperresponsiveness correlated well with the degree of airflow obstruction. Unlike asthmatics, however, most patients did not develop bronchoconstriction in response to RHL—that is, there was a discrepancy between the bronchial response to methacholine and RHL. We interpret these findings as support for the hypothesis that the increased response to methacholine in these patients is due primarily to the airflow obstruction, and that the lack of response to RHL reflects the absence of true hyperresponsiveness of the airway.

The presence of an increased response to methacholine in the absence of a bronchoconstrictor response to RHL requires an explanation, especially since in asthmatics there is a good correlation between responses to the two tests. We suggest, as have others, that the apparent hyperresponsiveness to methacholine is a reflection of the decreased airway calibre. There are several ways in which a reduction in FEV₁ could cause an increased responsiveness to a contractile agent. A given small change in the length of a smooth muscle cell will cause a larger proportional change in the diameter of a small airway than a large one. In addition, owing to Poiseuille's Law, as the airway narrows, a small change in the radius will result in a much larger increase in resistance, and decrease the airflow proportionately more. As the FEV₁ decreases, the absolute change in litres that corresponds to a 20% fall also decreases. This will magnify any measurement errors. In an attempt to minimise this latter problem, we included mainly patients with an FEV₁ greater than 1 litre. Finally, the change in deposition of the aerosol from peripheral to central in the presence of airflow obstruction may also increase the response when FEV₁ is used as the index of bronchoconstriction. In contrast to the response to methacholine, the decreased calibre of the airway did not alter the airway response to respiratory heat loss. This lack of response to respiratory heat loss in chronic airflow obstruction, despite responsiveness to prednisone and bronchodilators, has been reported recently. In this regard the patients with chronic bronchitis were responding as normal subjects, who do not develop bronchoconstriction in response to respiratory heat loss. This implies that the cold air has no inherent contractile properties, and that predisposing factors are present in asthmatic airways which promote the bronchoconstrictor response. The mechanism has not been established, but may be due to increased responsiveness of the muscle itself, easier release of mediators, or both. Interestingly, the three patients who responded to cold air had a greater response to methacholine than others with a similar degree of airflow obstruction. This suggests that in these subjects there was an increased response to methacholine resulting from obstruction and in addition true bronchial hyperresponsiveness as found in asthmatics. It may be possible to define an
expected response to methacholine for a given degree of airflow obstruction. A PC_{20} lower than this could then be used to support a diagnosis of asthma. More patients need to be studied, however, to confirm this possibility.

Problems of semantics are inevitable in the classification of patients with “chronic bronchitis.” The recognition of asthma in patients with chronic airflow obstruction is difficult. It has been conventional to try to avoid any possibility of associated asthma by excluding patients with atopy, eosinophilia, or a greater than 15% improvement in FEV_{1} after treatment with bronchodilator or steroid. None of these, however, are specific measurements. Atopy and eosinophilia are associated with asthma, but are not diagnostic; asthma may or may not be present. A specific percentage increase in FEV_{1} after treatment with bronchodilator or steroid may not be an indication of the same underlying pathological mechanism when the FEV_{1} is 1 l as when it is 2.5 l. We chose, therefore, to select for the study patients with a history of cigarette smoking who had chronic cough and sputum consistent with chronic bronchitis, and to document their characteristics. None of them gave a history to suggest that the primary diagnosis was asthma. This approach was supported by the results of the study. Firstly, exclusion of the patients with the above criteria or with a bronchoconstrictor response to respiratory heat loss did not alter the conclusion that the response to methacholine is determined by the level of airflow obstruction. Secondly, the usual exclusion criteria would not have applied to patients 10 and 12, who developed bronchoconstriction in response to respiratory heat loss. Thus further investigation is required to determine whether a bronchoconstrictor response to respiratory heat loss is a more specific test for the presence of asthma in chronic airflow obstruction. It may not be possible, however, to demonstrate a mild degree of asthma in patients with severe airflow obstruction since the amount of respiratory heat loss achieved at maximum ventilation when the FEV_{1} is less than a litre may be insufficient to stimulate bronchoconstriction.

Whether the response to methacholine in patients with chronic airflow obstruction is determined by the level of airway function, or whether bronchial hyperresponsiveness leads to the development of obstruction, cannot be answered without a longitudinal epidemiological study. Unfortunately a previous study, which showed a relationship between bronchial responsiveness and the rate of decline in FEV_{1}, measured the responsiveness at the end of the study period, and no conclusion can be drawn about cause and effect.

In summary, this study has shown that in chronic bronchitis the response to methacholine is related to the degree of airflow obstruction. This suggests that in the absence of additional information an increase in bronchial responsiveness to methacholine cannot be used to diagnose asthma in the presence of chronic airflow obstruction. The hypothesis that the presence of a bronchoconstrictor response to respiratory heat loss in patients with chronic airflow obstruction reflects true bronchial hyperresponsiveness requires further investigation. Further studies are needed to investigate the relationship between obstruction and true bronchial hyperresponsiveness.

We thank Glaxo Canada Ltd, Toronto, for the supply of salbutamol and the Upjohn Company of Canada Ltd, Don Mills, Ontario, for the supply of prednisone. We are grateful to Drs SO Pugsley, JLC Morse, and MT Newhouse for allowing us to study their patients, and to Dr EE Daniel for helpful discussion of the manuscript. This work was supported by a grant from the Medical Research Council of Canada. EHR is a fellow of the Ontario Ministry of Health.

References